Home Meeting Coverage ASH Annual Meeting ASH Annual MeetingMeeting CoverageMultimedia Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology Tuesday, March 7, 2017 Dr. Ansell, a speaker in the Special Education Session on Newly Approved Drugs, discusses the growing role of nivolumab in hematologic malignancies. Advertisement Recent Articles Oral Apixaban Noninferior to Subcutaneous Dalteparin for Preventing Recurrent Cancer-Associated VTE Wednesday, July 1, 2020 In patients with cancer-associated venous thromboembolism (VTE), treatment with oral apixaban was noninferior to subcutaneous dalteparin for the prevention of recurrent VTE, according to... July 2020 Volume 6 Issue 8 Wednesday, July 1, 2020 This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more. How I Treat in Brief: Anticoagulation in Patients With Obesity Wednesday, July 1, 2020 This month, Tzu-Fei Wang, MD, and Marc Carrier, MD, MSc, reviewed anticoagulation strategies for patients who are obese and therefore at risk of venous thromboembolism, atrial... Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma Wednesday, July 1, 2020 The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was... You Make the Call: Should this patient with DLBCL receive rituximab maintenance after R-CHOP? Wednesday, July 1, 2020 This month Ann S. LaCasce, MD, MMSc, discusses whether a patient with high-risk DLBCL should receive rituximab maintenance after R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride,... Current Issue July 2020 Volume 6 Issue 8 Wednesday, July 1, 2020 This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.